RBC Capital analyst Brian Abrahams raised the firm’s price target on Neumora Therapeutics (NMRA) to $31 from $24 and keeps an Outperform rating on the shares. The analyst notes that the timelines remain on track for the second half of 2024 in the first phase 3 readout from novel antidepressant navacaprant. RBC continues to believe that the prior data from the drug and others in the class bode well for potential efficacy and safety when they, as well as Johnson&Johnson (JNJ), reveal KOR antagonist data later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NMRA:
- Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Neumora Therapeutics reports Q4 EPS (71c), consensus (55c)
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
- Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer